Biopharmaceutical firm Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has announced that a conference call will be hosted later this week with a view to reviewing the fourth quarter as well as the full year results of 2017. The conference call will also be used as an opportunity to offer updates on the firm.
This comes in the wake of Infinity Pharmaceuticals adding new directors as it expanded the clinical leadership team as well as establishing a board to advice on science matters. The new members of the board include David Beier who possesses deep insights with regards to drug pricing, economics and healthcare policy.
“David’s deep insights on healthcare policy, economics and drug pricing, together with his perspectives as an advisor to the Parker Institute for Cancer Immunotherapy, will be invaluable as we advance IPI-549, a potentially first-in-class immuno-oncology medicine,” the chairman and chief executive officer of Infinity Pharmaceuticals, Adelene Perkins, said.
Currently Beier is Bay City Capital’s managing director and also sits on the boards of various institutions. Previously he has served on Genentech and Amgen’s senior management teams and is thus in a position to offer invaluable perspective with regards to the strategies that are likely to succeed for biotech firms. When Bill Clinton was president of the United States Beier was the vice president’s chief domestic policy advisor.
Infinity Pharmaceuticals has also appointed Marie-Louise Fjallskog as the clinical development vice president. She is currently Uppsala University’s associate professor in the oncology department and she possesses experience of more than two decades in drug development, translational research and clinical oncology. Before joining Infinity Pharmaceuticals Fjallskog led a clinical program at Novartis.
Additionally Infinity Pharmaceuticals has promoted Suresh Mahabhashyam to the position of risk management and safety vice president. Mahabhashyam possesses years of experience numbering more than 20 in epidemiology and medical practice. Besides Infinity Mahabhashyam has also worked at Allergan and Alexion.
With regards to establishing the scientific advisory board, several thought leaders have been appointed to the board and they include Dmitry Gabrilovich, Roy Herbst, Stephen Hodi and David Munn. The combined oncology experience of the advisory board will be key as Infinity makes progress in its product candidate – IPI-549.